Pharmacokinetic/pharmacodynamic analysis of antibiotic therapy in dentistry and stomatology;Análisis farmacocinético/farmacodinámico (PK/PD) de la antibioterapia en odontoestomatología

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 23, Issue 3, 2005, Pages 116-121

  Isla, Arantxazu ^a   Canut, Andrés ^b   Rodríguez Gascón, Alicia ^a   Labora, Alicia ^b   Ardanza Trevijano, Bruno ^c   Solinís, María Ángeles ^a   Pedraz, José Luis ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b HOSPITAL TXAGORRITXU   (Spain)

^c Cirugía Maxilofacial   (Spain)

Author keywords

Antibiotic; Orofacial odontogenic infection; Pharmacokinetics pharmacodynamics

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; CEFUROXIME AXETIL; CLINDAMYCIN; ERYTHROMYCIN; LEVOFLOXACIN; METRONIDAZOLE; METRONIDAZOLE PLUS SPIRAMYCIN; MINOCYCLINE; MOXIFLOXACIN; PENICILLIN V; RHODOGYL; SPIRAMYCIN; TELITHROMYCIN; UNCLASSIFIED DRUG;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DENTISTRY; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG EFFICACY; DRUG ELIMINATION; FUSOBACTERIUM NUCLEATUM; MINIMUM INHIBITORY CONCENTRATION; MOUTH CAVITY; MOUTH INFECTION; NONHUMAN; PEPTOSTREPTOCOCCUS; PORPHYROMONAS GINGIVALIS; PREDICTION; PREVOTELLA INTERMEDIA; STOMATOLOGY; TOOTH INFECTION;

EID: 16344379541     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: 10.1157/13072159     Document Type: Article

References (74)

1. Bascones Martínez A, Manso Platero FJ, Vadillo Martín JM, Bascones Ilundain J. Tratamiento de las infecciones orofaciales. En: García Sánchez JE, López R, Prieto J, editores. Antimicrobianos en medicina. Barcelona: Prous Science, 1999; p. 549-57.
2. Ciancio S. Use and abuse of antibiotics in periodontal therapy. Dent Econ 1993;83:98-100.
3. Palmer NOA, Martin MV, Pealing R. Pealing R, Ireland RS, Roy K, et al. Antibiotic prescribing knowledge of National Health Service general dental practitioners in England and Scotland. J Antimicrob Chemother 2001;47:233-7.
4. Jaunay T, Sambrook P, Goss A. Antibiotic prescribing practices by South Australian general dental practitioners. Aust Dent J 2000;45:179-86.
5. Roy K, Bagg J. Antibiotic prescribing by general dental practitioners in the Greater Glasgow Health Board, Scotland. Br Dent J 2000;188:674-6.
6. Dupon M, Cohere-Moleres MF, Dupon C, Vignau J, Darque J, Thielly P, et al. Evaluation of antibiotherapy in dental surgery (In French). Presse Med 1994;23:1803-8.
7. Yingling NM, Byrne BE, Hartwell GR. Antibiotic use by members of the American Association of Endodontists in the year 2000: report of national survey. J Endod 2002;28:396-404.
8. Dailey YM, Martin MV. Are antibiotics being used appropriately for emergency dental treatment? Br Dent J 2001;191:391-3.
9. Rehan HS, Singh C, Tripathi CD, Kela AK Study of drug utilization pattern in dental OPD at tertiary care teaching hospital. Indian J Dent Res 2001;12:51-6.
10. Dirección General de Aseguramiento y Planificación Sanitaria. Agencia de Evaluación de Tecnologías Sanitarias. Ministerio de Sanidad y Consumo. Informe sobre resistencia microbiana: ¿qué hacer? Med Clin (Barc) 1996;106: 267-375.
11. Alos JI, Carnicero M. Consumo de antibióticos y resistencia bacteriana a los antibióticos: "algo que te concierne". Med Clin (Barc) 1997;109:264-70.
12. Garcia de Lomas J, García Rey C, López L, Gimeno C and the Spanish Medical Surveillance Group for Respiratory Pathogens. Susceptibility patterns of bacteria causing community-acquired respiratory infections in Spain: the SAUCE project. J Antimicrob Chemother 2002;50(Suppl 2):21-6.
13. Schentag JJ, Swanson DJ, Smith IL. Dual individualization: antibiotic dosage calculation from the integration of in-vitro pharmacodynamics and in-vivo pharmacokinetics. J Antimicrob Chemother 1985;15(Suppl A):47-57.
14. Ellen RP, McCulloch CAG. Evidence versus empiricism: rational use of systemic antimicrobial agents for treatment of periodontitis. Periodontol 2000 1996;10:29-44.
15. Kuriyama T, Karasawa T, Nakasaea K, Saiki Y, Yamamoto E, Nakamura S. Bacteriolofic features and antimicrobial susceptibility in isolates from orofacial odontogenic infections. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000;90:600-8.
16. Liébana Ureña J, editor. Microbiología oral. Sección VIII: Microbiología de las enfermedades bucodentales. Madrid: McGraw-Hill, 1995.
17. Derive 4.11 for windows. Soft Warehouse, Inc. Hawai, 1996.
18. Jacobs MR. Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameterers. Clin Microbiol Infect 2001;7:589-96.
19. WinNonlin Standard 1.1 Scientific Consulting, Inc. North California, USA.
20. Andes D. Pharmacokinetic and pharmacodynamic properties of antimicrobials in the therapy of respiratory tract infections. Curr Op Infect Dis 2001;14:165-72.
21. Sánchez-Recio MM, Colino CI, Sánchez-Navarro A. A retrospective analysis of pharmacokinetic/pharmacodynarnic indices as indicators of the clinical efficacy of ciprofloxacin. J Antimicrob Chemother 2000;45:321-8.
22. Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J 1996;15:255-9.
23. Presston SL, Drusano GL, Berman AL, Fowler CL, Chow AT, Dornself B, et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 1998;279:125-9.
24. Kuriyama T, Karasawa T, Nakasawa K, Saiki Y, Yamamoto E, Nakamura S. Bacteriologic features and antimicrobial susceptibility in isolates from orofacial odontogenic infections. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000;90:600-8.
25. Loza E, Morosini MI, Negri MC, Almaraz F, Canton R, Baquero F. Estudio multicéntrico nacional de la actividad in vitro de moxifloxacino frente a patógenos respiratorios. Rev Esp Quimioter 2000;13:37-43.
26. Roche Y, Yoshimori RN. In vitro activity of spiramycin and metronidazole alone or in combination against clinical isolates from odontogenic abscesses. J Antimicrob Chemother 1997;40:353-7.
27. Sobottka I, Cachovan G, Stürenburg E, Ahlers MO, Laufs R, Platzeer U, et al. In vitro activity of moxifloxacin against bacteria isolated from odontogenic abscesses. Antimicrob Agents Chemother 2002;46:4019-21.
28. García de Lomas J, Gimeno C, Esteban E. Actividad antimicrobiana de telitromicina. Enferm Infecc Microbiol Clin 2001;19(Supl 2):7-14.
29. Hillier SL, Monda BJ. Peptostreptococcus, Propionibacterium, Eubacterium, and other nonsporeforming anaerobic gram-positive bacteria. En: Murray PR, Baron EJ, Pfaller MA, editors. Manual of clinical microbiology. 6th ed. Washington: ASM Press, 1995; p. 587-602.
30. Woodcock JM, Andrews JM, Boswell FJ, Brenwald NP, Wise R. In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrob Agents Chemother 1997;41:101-6.
31. Kuriyama T, Karasawa T, Nakasawa K, Yamamoto E, Nakamura S. Bacteriology and antimicrobial susceptibility of gram-positive cocci isolated from pus specimens of orofacial odontogenic infections. Oral Microbiol Immunol 2002;17:132-5.
32. Milazzo I, Blandino G, Musumeci R, Nicoletti G, Lo Bue AM, Speciale A. Antibacterial activity against periodontal anaerobic pathogens involved in systemic infections. Int J Antimicrob Agents 2002;20:451-6.
33. Matto J, Asikainen S, Väisänen ML, Von Troil-Lindén B, Könönen E, Saarela M, et al. Beta-lactamase production in Prevotella intermedia, Prevotella nigrescens, and Prevotella pollens genotypes and in vitro susceptibilities to select antimicrobial agents. Antimicrob Agents Chemother 1999;43: 2383-8.
34. Appelbaum PC, Spangler SK, Jacobs MR. β-lactamase production and susceptibilities to amoxicillin, amoxicillin-clavunanate, ticarcillin, ticarcillin-clavulanate, cefoxitin, imipenem, and metronidazole of 320 non-Bacteroides fragilis Bacteroides isolates and 129 fusobacteria from 28 U.S. Centres. Antimicrob Agents Chemother 1990;34:1546-50.
35. Sbordone L, Barone A, Ramaglia L, Ciaglia RN, Iacono VJ. Antimicrobal susceptibility of periodontopathic bacteria associated with failing implants. J Periodontol 1995;66:69-74.
36. Amsden GW, Gray CL. Serum and WBC pharmacokinetics of 1500 mg of azithromycin when given either as a single dose or over a 3 day period in healthy volunteers. J Antimicrob Chemother 2001;47:61-6.
37. Ballow CH, Amsden GW, Highet VS, Forrest A. Pharmacokinetics of oral azithromycin in serum, urine, polymorphonuclear leucocytes and inflammatory vs non-inflammatory skin blisters in healthy volunteers. Clin Drug Invest 1998;15:159-67.
38. Chien SC, Rogge MC, Gisclon LG, Curtin C, Wong F, Natarajan J, et al. Pharmacokinetic profile of levofloxacin following once-daily 500 milligram oral or intravenous doses. Antimicrob Agents Chemother 1997;41:2256-60.
39. Chien SC, Wong FA, Fowler CL, Callery SV, Williams RR, Nayak R, et al. Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers;. Antimicrob Agents Chemother 1998;42:885-8.
40. Dan M, Yampolsky E, Poch F. Serum concentrations and ex vivo inhibitory/bactericidal activity of clindamycin after administration of two oral dosages. Chemotherapy 1997;43:227-31.
41. Deppermann KM, Lode H, Höffken G, Tschink G, Kalz C, Koeppe P. Influence of ranitidine, pirenzepine, and aluminum magnesioum hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid. Antimicrob Agents Chemother 1989;33:1901-7.
42. Dunn CJ, Barradell LB. Azithromycin. A review of its pharmacological properties and use as 3-day therapy in respiratory tract infections. Drugs 1996;51:483-505.
43. Ernst ME, Ernst EJ, Klepser ME. Levofloxacin and trovafloxacin: the next generation of fluoroquinolones? Am J Health Syst Pharm 1997;54:2569-84.
44. Fish DN, Chow AT. The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet 1997;32:101-19.
45. Fraschini F, Scaglione F, Falchi M, Dugnani S, Mezzetti M, Cicchetti F, et al. Pharmacokinetics and tissue distribution of amoxicillin plus clavulanic acid after oral administration in man. J Chemother 1990;2:171-7.
46. Frydman AM, Le Roux Y, Desnottes JF, Kaplan P, Djebbar F. Pharmacokinetics of spiramycin in man. J Antimicrob Chemother 1988;22(Suppl B):93-103.
47. Gatti G, Flaherty J, Bubp J, White J, Borin M, Gambertoglio J. Comparative study of bioavailabilities and pharmacokinetics of clindamycin in healthy volunteers and patients with AIDS. Antimicrob Agents Chemother 1993;37:1137-43.
48. Ishii K, Saito Y, Itai S, Nemoto M, Takayama K, Nagai T. Comparative study of pharmacokinetic parameters between clarithromycin and erythromycin stearate in relation to their physicochemical properties. Drug Dev Ind Pharm 1998;24:129-37.
49. Jetlund O, Thurmann-Nielsen E, Walstad RA. Comparison of the serum and tissue concentrations of cefuroxime from cefuroxime axetil and phenoxymethylpenicillin in patients undergoing tonsillectomy. Int J Clin Pharmacol Res 1991;11:1-6.
50. Klotz U. Pharmacokinetic considerations in the eradication of Helicobacter pylori. Clin Pharmacokinet 2000;38:243-70.
51. Lalak NJ, Morris DL. Azithromycin clinical pharmacokinetics. Clin Pharmacokinet 1993;25:370-4.
52. Lang CC, Moreland TA, Davey PG. BioavailabUity of cefuroxime axetil: comparison of standard and abbreviated methods. J Antimicrob Chemother 1990;25:645-50.
53. Liu CM, Chen YK, Yang TH, Hsieh SY, Hung MH, Lin ET. High-performance liquid Chromatographie determination of clindamycin in human plasma or serum: application to the bioequivalency study of clindamycin phosphate injections. J Chromatogr B 1997;696:298-302.
54. Macdonald H, Kelly RG, Allen ES, Nobel JF, Kangis LA. Pharmacokinetic studies on minocycline in man. Clin Pharmacol Ther 1973;14:852-61.
55. a ed. Barcelona: Masson, 2001.
56. Miglioli PA, Pivetta P, Strazzabosco M, Orlando R, Okolicsanyi L, Palatini P. Effect of age on single- and multiple-dose pharmacokinetics of erythromycin. Eur J Clin Pharmacol 1990;39:161-4.
57. Montoya MA, Girard ME, Torres-Delgado S, Melgar-Morales O, Tinoco-Salazar CL. Relative bioavailability among metronidazole tablets. Gac Med Mex 1988;124:19-25.
58. Nix DE, Symonds WT, Hyatt JM, Wilton JH, Teal MA, Reidenberg P, et al. Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor and cefuroxime axetil in healthy volunteers. Pharmacotherapy 1997;17:121-5.
59. Overbosch D, Mattie H, Van Furth R. Comparative pharmacodynamics and clinical pharmacokinetics of phenoxymethylpenicillin and pheneticillin. Br J Clin Pharmacol 1985;19:657-68.
60. Plaisance KI, Drusano GL, Forrest A, Townsend RJ, Standiford HC. Pharmacokinetic evaluation of two dosage regimens of clindamycin phosphate. Antimicrob Agents Chemother 1989;33:618-20.
61. Quiding H, Arwidsson HG, Grahn Hakansson E, Grahnen A, Holm S. Saliva-resistant coating of tablets prevents oral release of penicillin: plasma but not saliva equivalence. Eur J Clin Pharmacol 1998;54:749-52.
62. Reed M. Clinical pharmacokinetics of amoxicillin and clavulanate. Pediatr Infect Dis J 1996;15:949-54.
63. Siegmund W, Zschiesche M, Franke G, Wilie A. Bioavailability of metronidazole formulations (Vagimid®). Pharmazie 1992;47:522-5.
64. Saivin S, Houin G. Clinical pharmacokinetics of doxycycline and minocycline. Clin Pharmacokinet 1988;15:355-66.
65. Trampuz A, Wenk M, Rajacic Z, Zimmerli W. Pharmacokinetics and pharmacodynamics of levofloxacin against Streptococcus pneumoniae and Staphylococcus aureus in human skin blister fluid. Antimicrob Agents Chemother 2000;44:1352-5.
66. Turnidge J. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Drugs 1999;58(Suppl 2):29-36.
67. Wise R, Bennet SA, Dent J. The pharmacokinetics of orally absorbed cefuroxime compared with amoxycillin/clavulanic acid. J Antimicrob Chemother 1984;13:603-10.
68. Zhanel GG, Noreddin AM. Pharmacokinetics and pharmacodynamics of the new fluorquinolones: focus on respiratory infections. Curr Op Pharmacol 2001;1:459-63.
69. Soman A, Honeybourne D, Andrews J, Jevons G, Wise R. Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemoter 1999;44:835-8.
70. Lubasch A, Keller I, Borner K, Koeppe P, Lode H. Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin and moxifloxacin after single oral administration in healthy volunteers. Antimicrob Agents Chemother 2000;44:2600-3.
71. Sullivan JT, Woodruff M, Lettieri J, Agarwal V, Krol GJ, Leese PP, et al. Pharmacokientics of once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone. Antimicrob Agents Chemother 1999;43:2793-7.
72. Stass H, Dalhoff A, Kubitza D, Scçúnhly U. Pharmacokinetics, safety and tolerability of ascending doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. Antimicrob Agents Chemother 1998;42: 2060-5.
73. Consejo General de Colegios Oficiales de Farmacéuticos. Catálogo de especialidades farmacéuticas, 2001; p. 1266-8.
74. Barman Balfour JA, Figgitt DP. Telitromicina. Drugs 2001;61:815-30.